Award
NIH Reporter #5R01FD008443-02
Retinoblastoma Phase II Expanded Access Clinical Trial
Recipient
TARGETED THERAPY TECHNOLOGIES, LLC
Award Amount
$650,000.00
Ceiling
$650,000.00
Awarded
August 03, 2026
Identifier
5R01FD008443-02
This award funds a Phase II clinical trial for retinoblastoma treatment using Topotecan Chemoplaque, aiming for FDA approval as the first approved therapy for this disease. The trial focuses on safety and efficacy in infants and children with retinoblastoma.
Description
A Phase II clinical trial supported by an FDA Orphan Drug Grant, focusing on expanding the use of Topotecan Chemoplaque for retinoblastoma treatment with a goal of FDA approval. The study emphasizes safety, efficacy, and potential resource benefits in low-resource settings.